Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 61 Stomach Neoplasms 46 Carcinoma, Non-Small-Cell Lung 37 Colorectal Neoplasms 24 Esophageal Squamous Cell Carcinoma 19 Lung Neoplasms 12 Rectal Neoplasms 11 Nasopharyngeal Carcinoma 11 Esophageal Neoplasms 11 Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 7 Cholangiocarcinoma 6 Uterine Cervical Neoplasms 5 Small Cell Lung Carcinoma 5 Liver Neoplasms 5 Triple Negative Breast Neoplasms 4 Recurrence 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Solid Tumor 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Carcinoma 3 Breast Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 aflutinib 9 Drug Therapy 9 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × sintilimab × Clear all

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡